ClinicalTrials.gg

Program

cevostamab

Its studies are mostly in Multiple Myeloma · Lupus Erythematosus, Systemic, led by Hoffmann-La Roche.

Furthest: phase 3, since Apr 22, 20268 company-led studies, 7 open or runningNext primary completion: Nov 18, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche87 open or runningphase 3since Apr 22, 2026Sep 5, 2017Nov 18, 2026phase 1 · NCT05646836
  • Named in Hoffmann-La Roche’s own pipeline as RG6160 cevostamab, phase 3, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2017First study: phase 1 study in Multiple MyelomaFirst studyNCT03275103 · 355 enrolled · United States, Australia, Canada and more
  2. May 27, 2021Phase 1 study in Multiple MyelomaNCT04910568 · 186 planned · United States, Australia, Canada and more
  3. Aug 24, 2022Phase 2 study in Multiple MyelomaNCT05535244 · 90 enrolled · United States, Australia, Belgium and more
  4. Dec 2, 2022Phase 1 study in Multiple MyelomaNCT05646836 · 90 enrolled · Australia, Denmark, Greece and more
  5. Apr 9, 2025Phase 1 study in Multiple MyelomaNCT06934044 · 20 enrolled · China
  6. Apr 22, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07555938 · 380 planned · United States, Australia, Brazil and more
  7. Jun 1, 2026Phase 1 study in Lupus Erythematosus, SystemicNCT07629583 · 46 planned · Australia, Brazil, China and more
  8. Sep 14, 2026Phase 2 study in Multiple MyelomaNCT07825064 · 45 planned · Germany

Ahead

  1. Nov 18, 2026Primary completion: phase 1 study in Multiple MyelomaNCT05646836
  2. Feb 26, 2027Primary completion: phase 2 study in Multiple MyelomaNCT05535244
  3. Oct 31, 2028Primary completion: phase 3 study in Multiple MyelomaNCT07555938
  4. Nov 15, 2028Primary completion: phase 1 study in Multiple MyelomaNCT06934044

TargetBeta

“A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen foun…”NCIt, read by Claude
“A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found o”NCIt, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07825064Multiple Myeloma · Germany2RecruitingApr 13, 202945
NCT07629583Lupus Erythematosus, Systemic · Australia, Brazil, China and more1RecruitingMar 29, 203046
NCT07555938Multiple Myeloma · United States, Australia, Brazil and more3RecruitingOct 31, 2028380
NCT06934044Multiple Myeloma · China1Active, not recruitingNov 15, 202820
NCT05646836Multiple Myeloma · Australia, Denmark, Greece and more1Active, not recruitingNov 18, 202690
NCT05535244Multiple Myeloma · United States, Australia, Belgium and more2Active, not recruitingFeb 26, 202790
NCT04910568Multiple Myeloma · United States, Australia, Canada and more1RecruitingDec 21, 2028186
NCT03275103Multiple Myeloma · United States, Australia, Canada and more1CompletedJan 7, 2026355

How it is read

Names in the registry

  • “Cevostamab”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.